肾癌的放射治疗选择。
Radiation therapy options in kidney cancer.
机构信息
University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, Ohio, USA.
Department of Radiation Oncology, Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
出版信息
Curr Opin Support Palliat Care. 2023 Dec 1;17(4):308-314. doi: 10.1097/SPC.0000000000000683. Epub 2023 Oct 26.
PURPOSE OF REVIEW
In this review, the authors discuss the use of stereotactic body radiation therapy (SBRT) for the treatment of primary and metastatic renal cell carcinoma (RCC).
RECENT FINDINGS
For primary RCC treated with SBRT, local control is estimated at >95%, and grade 3-4 toxicity is limited at ≤5%. The difference in glomerular filtration rate pretreatment versus posttreatment was about 7.7 ml/min. For metastatic RCC treated with SBRT, the 1-year local control is ~90%. The incidence of any grade 3-4 toxicity is ~1%. Several ongoing trials are evaluating SBRT in combination or in lieu of systemic therapy. There are many unknowns remaining in the treatment of RCC, including tumor prognostication, treatment selection, and treatment delivery.
SUMMARY
Stereotactic body radiation therapy is a safe and effective treatment option for patients with primary and metastatic RCC.
目的综述
在这篇综述中，作者讨论了立体定向体放射治疗（SBRT）在治疗原发性和转移性肾细胞癌（RCC）中的应用。
最近的发现
对于接受 SBRT 治疗的原发性 RCC，局部控制率估计超过 95%，3-4 级毒性的发生率有限，≤5%。治疗前后肾小球滤过率的差异约为 7.7ml/min。对于接受 SBRT 治疗的转移性 RCC，1 年局部控制率约为 90%。任何 3-4 级毒性的发生率约为 1%。目前正在进行多项临床试验，评估 SBRT 联合或替代全身治疗的效果。在 RCC 的治疗中，仍有许多未知因素，包括肿瘤预后、治疗选择和治疗实施。
总结
SBRT 是治疗原发性和转移性 RCC 的一种安全有效的治疗选择。
Zotero 插件